← Human Trials & Peer-Reviewed Studies
Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
Plain-language guide to PMID 22517769 (2012): double-blind randomized controlled trial study of Glucagon.
Key Facts
- PMID
- 22517769
- Journal
- American journal of physiology. Gastrointestinal and liver physiology
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Camilleri M et al. (11 authors)
- DOI
- 10.1152/ajpgi.00076.2012
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glucagon, published as a randomized controlled trial.
Their objective was to assess effects of ROSE-010 on several gastrointestinal (GI) motor and bowel functions in constipation-predominant IBS (IBS-C).
Why It Was Studied
The researchers measured GI and colonic transit by validated scintigraphy and gastric volumes by single-photon emission computed tomography.
The primary end points were half time of gastric emptying of solids, colonic transit geometric center at 24 h, and gastric accommodation volume.
Who Took Part
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, women only.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.
As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Glucagon, giving a reference point.
The Glucagon group and the comparison group ran side by side rather than switching.
What Was Measured
The researchers measured GI and colonic transit by validated scintigraphy and gastric volumes by single-photon emission computed tomography.
The primary end points were half time of gastric emptying of solids, colonic transit geometric center at 24 h, and gastric accommodation volume.
Topics PubMed links to this paper include Area Under Curve, Constipation, Defecation, Endpoint Determination, Gastric Emptying, Gastrointestinal Agents and Gastrointestinal Motility.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Glucagon.
The publication is from 2012 (American journal of physiology. Gastrointestinal and liver physiology), a journal based in United States.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.